EUCTR2016-000859-27-NL进行中（未招募）1 期
Efficacy and mode of action of apremilast (Otezla) in moderate hidradenitis suppurativa. An exploratory pilot study.
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Key inclusion criteria: adult (= 18 years of age) male or female patients with moderate HS according to a PGA of 3 on the 5-point HS-Physician Global Assessment (HS-PGA); HS of more than 6 months duration; have lesions in at least two anatomical locations.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 10
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Key exclusion criteria: contraindication for apremilast; previous use of apremilast; have any current and/or recurrent clinically significant skin condition in the treatment area other than HS; presence of other uncontrolled major disease; pregnant or lactating women.
研究者
相似试验
进行中（未招募）
1 期
Preliminary efficacy and safety of Apremilast in the treatment of acne conglobata: A phase II, single centre, open label, proof of concept study for the treatment of acne conglobata with the PDE-4 inhibitor Apremilast (APACCO-Study)EUCTR2017-002612-14-DEFraunhofer Gesellschaft for its Institute Fraunhofer Institute for Molecular Biology and Applied Ecology (IME)16
进行中（未招募）
4 期
Checking safety and effectiveness of Apremilast tablets in patients with Lichen Planus, an inflammatory disorder that appears as purplish, flat-topped bumps when it affects the skin.CTRI/2020/05/025197Rajiv Gandhi Medical College and Chhatrapati Shivaji Maharaj Hospital
尚未招募
2 期
Evaluation of effective and safe use of a new drug Apremilast [a Phosphodiesterase enzyme inhibitor (PDE-4 inhibitor)] in patients suffering from unstable white patch-a skin condition called vitiligo.CTRI/2019/07/020234AIIMS JODHPUR
尚未招募
4 期
The Efficacy and Safety of Oral Apremilast in comparison to that of Oral Methotrexate in the management of Interface DermatitisCTRI/2022/01/039139Krishna institute of medical sciences karad
已完成
3 期
A Phase 3 Randomized, Double-blind Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Subjects With Active Behçet's DiseaseBehçet's SyndromeNCT02307513Amgen207